Global Dengue Vaccine Market Size By Type (CYD-TDV, DENVax or TAK-003), By Application (Government Institutions, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Dengue Vaccine Market was valued at USD 485 million in 2023 and is projected to surpass USD 1.65 billion by 2031, expanding at a robust CAGR of 16.5% during the forecast period from 2023 to 2031. The growth of the market is primarily driven by the rising prevalence of dengue fever globally, increasing government vaccination initiatives, and growing awareness about vector-borne diseases. Additionally, the development and approval of advanced multivalent dengue vaccines that provide protection against multiple dengue virus serotypes are contributing significantly to the market expansion.

Drivers:

Increasing Prevalence of Dengue Fever:

The rise in the number of dengue cases, particularly in tropical and subtropical regions, is fueling the demand for effective preventive solutions like vaccines. According to the WHO, nearly 400 million dengue infections occur annually worldwide.

Government Immunization Programs:

Several governments, especially in dengue-endemic regions, are promoting immunization programs and vaccination campaigns to control the spread of dengue fever, positively impacting market growth.

Technological Advancements in Vaccine Development:

Continuous research and innovations have led to the development of tetravalent dengue vaccines that offer cross-protection against all four serotypes of the dengue virus, thereby enhancing vaccine efficacy.

Restraints:

High Development and Regulatory Costs:

Developing dengue vaccines involves significant R&D investment and complex regulatory processes, which may pose a challenge for new market entrants.

Limited Access in Low-Income Regions:

Despite the rising demand, access to dengue vaccines remains limited in certain low-income regions due to high costs and weak healthcare infrastructure.

Opportunity:

Expansion in Emerging Economies:

Emerging economies in Asia-Pacific and Latin America, where dengue fever is highly prevalent, present lucrative growth opportunities for vaccine manufacturers.

Development of Next-Generation Vaccines:

Ongoing clinical trials focusing on next-generation dengue vaccines with improved efficacy and safety profiles offer significant market potential.

Market by System Type Insights:

Based on vaccine type, the Tetravalent Vaccine segment dominated the market in 2023, owing to its ability to provide protection against all four dengue virus serotypes. This segment is expected to maintain its leadership during the forecast period, driven by increasing product approvals and expanded immunization coverage.

Market by End-use Insights:

By end-use, the Public Health Institutions segment accounted for the largest market share in 2023. The role of government health bodies in conducting mass vaccination programs, especially in highly endemic regions, has fueled the dominance of this segment.

Market by Regional Insights:

Asia-Pacific led the global dengue vaccine market in 2023, accounting for the largest revenue share. Countries like India, Indonesia, the Philippines, and Thailand are the major contributors to the region’s market growth due to the high incidence of dengue. Latin America is expected to register the highest growth rate during the forecast period, supported by expanding vaccination initiatives and increasing awareness.

Competitive Scenario:

Key players operating in the global dengue vaccine market include Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Panacea Biotec, VBI Vaccines Inc., Butantan Institute, and Biological E. Limited. These companies are focusing on strategic partnerships, product launches, and geographical expansion to strengthen their market position.

Key Market Developments:

In 2023, Takeda Pharmaceutical received approval for its tetravalent dengue vaccine "QDENGA" in several countries, expanding its market presence.

Sanofi Pasteur announced the development of next-generation dengue vaccines with enhanced safety profiles in 2024.

The Serum Institute of India collaborated with international research bodies in 2024 to develop affordable dengue vaccines for low-income countries.

Scope of Work – Global Dengue Vaccine Market

Report Metric Details

Market Size (2023) USD 485 million

Projected Market Size (2031) USD 1.65 billion

CAGR (2023-2031) 16.5%

Key Segments by Vaccine Type Monovalent Vaccine, Tetravalent Vaccine

Key Segments by End-Use Public Health Institutions, Private Healthcare

Leading Region Asia-Pacific

Key Players Sanofi Pasteur, Takeda Pharmaceutical, Merck, GlaxoSmithKline, Serum Institute of India, Panacea Biotec, VBI Vaccines Inc., Butantan Institute, Biological E. Ltd.

FAQs:

1. What is the current market size of the Global Dengue Vaccine Market?

The Global Dengue Vaccine Market was valued at USD 485 million in 2023.

2. What is the major growth driver of the Global Dengue Vaccine Market?

The increasing prevalence of dengue fever and rising government immunization initiatives are the key growth drivers of the market.

3. Which is the largest region during the forecast period in the Global Dengue Vaccine Market?

Asia-Pacific is the largest region in the Global Dengue Vaccine Market during the forecast period.

4. Which segment accounted for the largest market share in the Global Dengue Vaccine Market?

The Tetravalent Vaccine segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Dengue Vaccine Market?

Key market players include Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., GlaxoSmithKline plc, and Serum Institute of India Pvt. Ltd.